Americans shopping for sunscreen this summer will soon find a new active ingredient on store shelves for the first time in roughly two decades. The Food and Drug Administration issued a final administrative order adding bemotrizinol to the over-the-counter sunscreen monograph, permitting concentrations up to 6 percent. The decision, carried out through the agency’s OTC Monograph Order Request process, opens the door for U.S. manufacturers to reformulate products with a UV filter that has been available in other countries for years.
What bemotrizinol changes for sunscreen buyers and formulators
The practical effect is straightforward: companies can now include bemotrizinol as an active ingredient in OTC sunscreen sold in the United States without filing a separate new drug application. The ingredient was added to Monograph M020, which governs sunscreen drug products for over-the-counter human use. Before this order, the list of permitted sunscreen actives had not grown in about 20 years, according to the FDA, while the Associated Press puts the gap at more than 25 years. Either way, the freeze was long enough that dermatologists, consumer advocates, and sunscreen makers had grown frustrated with the pace of U.S. ingredient approvals even as European and Asian regulators cleared newer filters.
Bemotrizinol already has a track record abroad. According to the Associated Press, DSM is expected to bring the ingredient to the U.S. market under the trade name Parsol Shield. The exact date of first retail availability has not been disclosed, but the regulatory clearance itself removes the largest barrier to commercialization. For consumers, the addition could translate into broader choices in broad-spectrum protection at a time when skin-cancer prevention remains a pressing public health concern.
How the OMOR pathway replaced decades of rulemaking gridlock
The mechanism behind this approval matters as much as the ingredient itself. Congress reformed the OTC monograph system in 2020, replacing the old notice-and-comment rulemaking process with administrative orders under Section 505G of the Federal Food, Drug, and Cosmetic Act. The new pathway, known as the OTC Monograph Order Request, lets outside parties petition the FDA to add or change conditions in a monograph without the years-long Federal Register rulemaking cycle that had stalled sunscreen ingredient reviews for decades.
The final order, designated OTC000039, amends Monograph M020. A proposed version of the order appeared in the Federal Register in December 2025, opening a public comment window before the agency finalized the action. That timeline, from proposed order to final inclusion, is far shorter than the multi-decade stall that characterized earlier sunscreen ingredient petitions under the old rulemaking framework.
Whether the OMOR process can consistently cut ingredient-review timelines by 40 percent or more compared with pre-2020 proposals is a hypothesis worth tracking. The bemotrizinol case is the first real test. If future order numbers in the OTC000039 series move at a similar pace, the reformed pathway will have demonstrated a clear speed advantage. If they do not, the bottleneck may have simply shifted from procedural design to FDA staffing and scientific review capacity.
Gaps in the public record and what to watch next
Several questions remain unanswered in the public docket. The FDA’s order detail page and the Federal Register notice do not include raw clinical or stability data files for bemotrizinol. International safety summaries referenced in news coverage are not reproduced or linked in the agency’s formal record. No direct statements from FDA officials or the sponsor appear in the primary regulatory documents that have been published so far. Consumers and independent researchers looking for the underlying safety evidence will need to wait for additional disclosures or file Freedom of Information Act requests.
The timeline discrepancy between the FDA’s own framing, which describes the first expansion in approximately 20 years, and the Associated Press reporting, which calls it the first new ingredient in more than 25 years, reflects ambiguity about which prior approval serves as the baseline. The difference does not change the significance of the action, but it does signal that even basic historical benchmarks in sunscreen regulation are not cleanly settled.
For shoppers, the immediate next step is simple: look for bemotrizinol on the active-ingredients panel of sunscreen products once manufacturers begin reformulating. DSM’s expected launch of Parsol Shield will be the first commercial signal that the regulatory change has reached retail shelves. Until then, existing FDA-approved sunscreen actives remain available and effective, and the addition of bemotrizinol expands rather than replaces the current options. The broader question is whether the OMOR pathway will keep delivering new ingredients at a pace that matches the science available overseas, or whether bemotrizinol will stand alone as an isolated success for years to come.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
